Gatta A, Merkel C, Grassetto M, Milani L, Zuin R, Ruol A
Nephron. 1982;30(4):364-7. doi: 10.1159/000182519.
Mean renal blood flow (MRBF), cortical blood flow (CBF), glomerular filtration rate (GFR), heart rate, arterial blood pressure, Na+ and K+ excretion were determined before and 10 min after intrarenal administration of dihydroergocristine (0.017 mg/kg b.w.) in 13 patients suffering from liver cirrhosis. Cardiac output was also determined in 6 patients. Baseline values of MRBF and CBF were significantly lower in cirrhotics than in the 14 control subjects. Following intrarenal administration of the drug, renal hemodynamic parameters increased significantly, while GFR decreased. Systemic hemodynamic parameters, diuresis, Na+ and K+ excretions were unchanged. These data show that dihydroergocristine has a renal vasodilator effect, probably mediated by alpha-adrenergic blockade. The effect probably is prevalent at the postglomerular site, where the increase in vascular resistance is greatest. The effect of the drug suggests that patients with liver cirrhosis have enhanced renal sympathetic activity which is, at least in part, responsible for the renal vasoconstriction.
在13例肝硬化患者中，测定了肾内注射双氢麦角汀（0.017mg/kg体重）前及注射后10分钟的平均肾血流量（MRBF）、皮质血流量（CBF）、肾小球滤过率（GFR）、心率、动脉血压、钠和钾排泄量。还对6例患者测定了心输出量。肝硬化患者的MRBF和CBF基线值显著低于14名对照受试者。肾内注射该药物后，肾血流动力学参数显著增加，而GFR降低。全身血流动力学参数、利尿、钠和钾排泄量未发生变化。这些数据表明，双氢麦角汀具有肾血管舒张作用，可能是由α-肾上腺素能阻滞介导的。这种作用可能在肾小球后部位最为明显，此处血管阻力增加最大。该药物的作用表明，肝硬化患者的肾交感神经活性增强，这至少部分是肾血管收缩的原因。
